COX-2 inhibitors: a novel strategy in the management of breast cancer. Issue 4 (April 2016)

• Record Type: Journal Article
• Authors: Regulski, Miłosz; Regulska, Katarzyna; Prukała, Wiesław; Piotrowska, Hanna; Stanisz, Beata; Murias, Marek
• Is Part Of: Drug discovery today. Volume 21:Issue 4(2016)
• Page Start: 598
• Page End: 615
• Publication Date: 2016-04
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2015.12.003
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Cyclooxygenase-2 participates in carcinogenesis. Cyclooxygenase-2 inhibitors can be used in breast cancer prophylaxis or therapy. Trans -stilbene derivatives are a novel class of cyclooxygenase inhibitors. In silico techniques are auxiliary means in the discovery of new drugs. Abstract : Cyclooxygenase-2 (COX-2) inhibitors are common anti-inflammatory drugs with pleiotropic, endogenous actions that could be useful in the management of breast cancer. Here, we provide a complete understanding of the biochemistry of COX-2 and discuss the various molecular mechanisms behind its increased expression in breast cancer. We also analyze the possible mechanisms responsible for the anticancer effect of COX-2 inhibitors and provide an overview of the available preclinical and clinical data on the use of COX-2 inhibitors in breast cancer. Finally, we describe a mathematical model of the relation between the structure and biological potency of promising new COX-2 inhibitors ( trans -stilbenes) using a 2D quantitative structure–activity relationship (QSAR) technique.